VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) Test
Welcome to DNA Labs UAE, a leading genetic laboratory offering a wide range of diagnostic tests. In this blog, we will discuss the VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) test, its cost, symptoms, diagnosis, and other relevant information.
Test Details
The VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) test is a laboratory test used to evaluate the activity of von Willebrand factor (vWF) in the blood. Von Willebrand factor is a protein that plays a crucial role in blood clotting. It helps platelets stick to the site of blood vessel injury, promotes platelet aggregation, and stabilizes the clot.
The vWF:CB test measures the ability of vWF to bind to collagen, which is a component of the blood vessel wall. This binding activity is essential for platelet adhesion and clot formation. By measuring the vWF:CB, healthcare providers can assess the functionality of vWF and determine if there is any deficiency or dysfunction in the protein.
Symptoms and Diagnosis
The vWF:CB test is primarily used to diagnose and monitor von Willebrand disease (VWD), which is a bleeding disorder caused by a deficiency or dysfunction of vWF. It can help differentiate between different types of VWD and guide appropriate treatment decisions.
The test is usually performed on a blood sample collected from a vein. The blood is then analyzed in the laboratory to measure the vWF:CB. The results are reported as a percentage, indicating the amount of vWF activity compared to normal levels.
Abnormal results of the vWF:CB test may indicate a potential vWF-related disorder, such as VWD. However, further testing, including vWF antigen and vWF ristocetin cofactor activity tests, is usually required to confirm the diagnosis and determine the specific subtype of VWD.
Test Cost and Sample Collection
The cost of the VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) test is AED 2320.0.
To perform the test, a sample of 3 mL whole blood is required in 1 Blue Top (Sodium Citrate) tube. The sample should be mixed thoroughly by inversion and transported to the lab within 4 hours. If immediate transportation is not possible, the sample can be processed to make Platelet Poor Plasma (PPP).
To make PPP, the sample should be centrifuged at 3600 rpm for 15 minutes. The supernatant should then be transferred to a clean plastic tube and centrifuged again at the same speed for 15 minutes. Finally, the supernatant (PPP) should be transferred to a labeled, clean plastic screw-capped vial and frozen immediately. It is important not to thaw the sample.
Overnight fasting is preferred before the test. Additionally, a duly filled Coagulation Requisition Form (Form 15) is mandatory for the test.
Report Delivery and Test Department
The sample should be provided on Wednesday by 11 am, and the report will be delivered on the same day by 6 pm.
The VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) test falls under the COAGULATION department.
Conclusion
The VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWFCB) test is a valuable tool in evaluating the functionality of von Willebrand factor and diagnosing von Willebrand disease. It helps healthcare providers assess the risk of bleeding and develop appropriate treatment plans for individuals with vWF-related disorders.
If you suspect any symptoms related to von Willebrand disease or require further information about the vWFCB test, please consult a hematologist.
Test Name | VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY vWFCB Test |
---|---|
Components | |
Price | 2320.0 AED |
Sample Condition | 3 mL whole blood in 1 Blue Top (Sodium Citrate) tube. Mix thoroughly by inversion. Transport to Lab within 4 hours. If this is not possible, make PPP within 1 hour of collection as follows: Centrifuge sample at 3600 rpm for 15 min. & transfer supernatant to a clean plastic tube. Centrifuge this supernatant again at 3600 rpm for 15 mins. & finally transfer the supernatant (PPP) to 1 labelled, clean plastic screw capped vial. FREEZE IMMEDIATELY. Ship frozen. DO NOT THAW. Overnight fasting is preferred. Duly filled Coagulation Requisition Form (Form 15) is mandatory. |
Report Delivery | Sample Wed by 11 am; Report Same day by 6 pm |
Method | Chemiluminscent Immunoassay |
Test type | Disorders of Coagulation |
Doctor | Hematologist |
Test Department: | COAGULATION |
Pre Test Information | Overnight fasting is preferred. Duly filled Coagulation Requisition Form (Form 15) is mandatory. |
Test Details |
The VON WILLEBRAND FACTOR COLLAGEN BINDING ACTIVITY (vWF:CB) test is a laboratory test used to evaluate the activity of von Willebrand factor (vWF) in the blood. Von Willebrand factor is a protein that plays a crucial role in blood clotting. It helps platelets stick to the site of blood vessel injury, promotes platelet aggregation, and stabilizes the clot. The vWF:CB test measures the ability of vWF to bind to collagen, which is a component of the blood vessel wall. This binding activity is essential for platelet adhesion and clot formation. By measuring the vWF:CB, healthcare providers can assess the functionality of vWF and determine if there is any deficiency or dysfunction in the protein. The vWF:CB test is primarily used to diagnose and monitor von Willebrand disease (VWD), which is a bleeding disorder caused by a deficiency or dysfunction of vWF. It can help differentiate between different types of VWD and guide appropriate treatment decisions. The test is usually performed on a blood sample collected from a vein. The blood is then analyzed in the laboratory to measure the vWF:CB. The results are reported as a percentage, indicating the amount of vWF activity compared to normal levels. Abnormal results of the vWF:CB test may indicate a potential vWF-related disorder, such as VWD. However, further testing, including vWF antigen and vWF ristocetin cofactor activity tests, is usually required to confirm the diagnosis and determine the specific subtype of VWD. Overall, the vWF:CB test is a valuable tool in evaluating the functionality of vWF and diagnosing von Willebrand disease. It helps healthcare providers assess the risk of bleeding and develop appropriate treatment plans for individuals with vWF-related disorders. |